OBJECTIVE: To investigate the status of medication errors（ ME） in women and children in Beijing Obstetrics and Gynecology Hospital

Capital Medical University（ hereinafter referred to as "our hospital"）

and to discuss the prevention strategies

so as to provide reference for improving medication safety in this field. METHODS:ME reports of our hospital reported on Chinese clinical drug safety monitoring network from 2016 to 2019 were collected and analyzed. Items included the triggering links

classification

involved drugs

error content

triggering factors and injury incidents. RESULTS: A total of 394 cases of ME were collected. ME reports of B

C

D

and E accounted for92. 39%（ 364 cases）

3. 81%（ 15 cases）

1. 78%（ 7 cases） and 2. 03%（ 8 cases）

respectively. There were no ME reports of A and F to I. Internal errors that did not reach the patient accounted for 90. 10%（ 355 cases）. Totally75. 00%（ 6 cases） of ME reports of E were induced by the patients’ medication error. And 23. 60%（ 93 cases） of ME were special population（ including pregnant women

lactating women and infants）. The top three drugs ranked by the number of ME reports were respectively Misoprostol tablets

Progesterone soft capsules and Dydrogesterone tablets. In terms of classifications of ME contents

the most errors in clinicians ’ prescriptions（ medical order） were mainly dosage

route of administration and frequency of administration. The error of variety was the most in drug dispensing by pharmacists. Medication errors focused on dosage and administration techniques. The main factors of ME were imperfect information system

lack of knowledge and similar drug names. Drugs with similar appearance and sound mainly involved three categories of Chinese patent medicine for gynecology

estrogen and progesterone and topical drugs for gynecology. CONCLUSIONS: Attention should be paid to the prevention of ME in women and children

and relevant strategies should be developed to reduce the occurrence of ME.